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Abstract
Background: The bone marrow (BM) is a main organ at risk in Lu-177-PSMA-617 therapy of prostate cancer and
Lu-177-Octreotate therapy of neuroendocrine tumours. BM dosimetry is challenging and time-consuming, as
different sequential quantitative measurements must be combined. The BM absorbed dose from the remainder of
the body (ROB) can be determined from sequential whole-body planar (WB-P) imaging, while quantitative Lu-177-
SPECT allows for more robust tumour and organ absorbed doses. The aim was to investigate a time-efficient and
patient-friendly hybrid protocol (HP) for the ROB absorbed dose to the BM. It combines three abdominal
quantitative SPECT (QSPECT) scans with a single WB-P acquisition and was compared with a reference protocol (RP)
using sequential WB-P in combination with sequential QSPECT images. We investigated five patients receiving 7.
4 GBq Lu-177-Octreotate and five patients treated with 3.7 GBq Lu-177-PSMA-617. Each patient had WB-P and
abdominal SPECT acquisitions 24 (+ CT), 48, and 72 h post-injection. Blood samples were drawn 30 min, 80 min,
24 h, 48 h, and 72 h post-injection. BM absorbed doses from the ROB were estimated from sequential WB-P images
(RP), via a mono-exponential fit and mass-scaled organ-level S values. For the HP, a mono-exponential fit on the
QSPECT data was scaled with the activity of one WB-P image acquired either 24, 48, or 72 h post-injection (HP24,
HP48, HP72). Total BM absorbed doses were determined as a sum of ROB, blood, major organ, and tumour
contributions.
Results: Compared with the RP and for Lu-177-Octreotate therapy, median differences of the total BM absorbed
doses were 13% (9–17%), 8% (4–15%), and 1% (0–5%) for the HP24, HP48, and HP72, respectively. For Lu-177-PSMA-
617 therapy, total BM absorbed doses deviated 10% (2–20%), 3% (0–6%), and 2% (0–6%).
Conclusion: For both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, BM dosimetry via sequential QSPECT
imaging and a single WB-P acquisition is feasible, if this WB-P image is acquired at a late time point (48 or 72 h
post-injection). The reliability of the HP can be well accepted considering the uncertainties of quantitative Lu-177
imaging and BM dosimetry using standardised organ-level S values.
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Background
Over the recent years, radionuclide therapy using Lu-177-
Octreotate and Lu-177-PSMA-617 evolved as a promising
approach for the treatment of metastasised and inoperable
neuroendocrine tumours (NET) and metastasised,
castration-resistant prostate cancer (mCRPC), respectively
[1–3]. The red or active bone marrow (BM) represents a
main organ at risk in radionuclide therapy [4–8]. Bone
marrow toxicity is particularly of concern in Lu-177-
PSMA-617 therapy, as patients suffering from mCRPC
often present with a high burden of bone metastases. The
latter may cause pronounced activity accumulations in
close proximity to the regions which potentially bear active
marrow. At these locations, especially the γ-component of
the Lu-177 decay might lead to a significant photon
cross-irradiation of the bone marrow [9]. However, for
Lu-177-Octreotate therapy, the bone marrow is also con-
sidered as an organ at risk, as patients with progressive can-
cer disease usually already underwent several pre-therapies
such as external radiotherapy or chemotherapy [3, 4]. These
pre-therapies may have interfered with the haematological
function of the bone marrow. Thus, bone marrow dosim-
etry is highly recommended in these patients for risk reduc-
tion of marrow toxicities and, at the same time, an as high
as possible tumour absorbed dose [10].
The total bone marrow absorbed dose is composed of
different contributions originating from various activity
source regions: (1) the bone marrow self-absorbed dose
including the active bone marrow cells, the extracellular
fluid, and the blood cells; (2) activity accumulations in
the remaining skeleton composed of compact bone or
fatty tissue (yellow or inactive marrow); (3) the
cross-absorbed dose by major organs or tumours; and
(4) the cross-irradiation coming from the remainder of
the body (ROB; whole body minus specific or unspecific
accumulations in the other source regions) [11]. Each
absorbed dose component requires a dedicated measure-
ment procedure to derive its respective time-activity
curve (TAC) and the source-specific time-integrated ac-
tivity. The cumulated actvity-to-absorbed-dose conver-
sion is usually performed via pre-calculated and
standardised organ-level S values [11].
The appropriate data collection to accurately quantify the
various possible source regions is challenging and leads to
both a high clinical workload and long patient examination
times, if bone marrow dosimetry shall be routinely
performed in the clinic. For Lu-177-Octreotate or
Lu-177-PSMA-617 therapy, the bone marrow absorbed
dose from the major accumulating organs (DBM← organs),
the ROB (DBM←ROB), and the blood (DBM← blood) can be
determined from sequential quantitative SPECT images, se-
quential quantitative whole-body planar images, and mul-
tiple blood samples, respectively, in combination with the
corresponding S values [8, 9, 11–13]. However, despite the
high metastatic load which might be observed for NET and
mCRPC patients, it is challenging to explicitly consider the
bone marrow absorbed dose from activity accumulations in
the tumours (DBM← tumours) via standardised and
pre-calculated tumour-to-bone marrow S values, as the lat-
ter intrinsically cannot consider the large inter-patient vari-
ability of the shape, size, and distribution of all lesions [14].
Our institutional protocol determines the absorbed dose
contribution from the ROB via sequential whole-body pla-
nar images [11], which are acquired at three time points at
24, 48, and 72 h post-injection. In addition, we decided to
derive organ (e.g. kidneys) and tumour absorbed doses
from sequential quantitative SPECT measurements for
improved organ and tumour dosimetry [15–18]. However,
full whole-body quantitative Lu-177 SPECT is still not
commonly used in the clinic, implicating the need of con-
secutive planar and SPECT imaging at each time point to
obtain both reliable bone marrow absorbed doses from
the ROB and reliable organ or tumour absorbed doses
[19]. Particularly, the increased examination time in case
of consecutive SPECT and whole-body planar imaging
leads to an increased clinical workload and patient dis-
comfort, as patients with progressive cancer disease may
suffer from a bad health condition. Thus, the aim of this
work was to derive a time-efficient, patient-friendly, and
simplified bone marrow dosimetry protocol for clinical
routine. Therefore, we investigated the possibility to re-
duce the number of image acquisitions from three
whole-body planar and three quantitative SPECT scans
(reference protocol (RP)) to a single whole-body planar
acquisition while maintaining the institution’s usual se-
quential quantitative SPECT protocol (hybrid protocol
(HP)). Further, we investigated the effect of this image re-
duction on the bone marrow absorbed dose from the
ROB and on the total bone marrow dose (DBM← total), to
prove whether the proposed hybrid protocol provides
comparable absorbed dose estimates for both
Lu-177-Octreotate and Lu-177-PSMA-617 therapy. For
the determination of the total bone marrow absorbed
dose, the energy depositions in the bone marrow due to
activity accumulations in the ROB, blood, major organs,
and tumours were considered. Furthermore, we deter-
mined the best-suited time point for this single
whole-body planar image acquisition with respect to the
time points available in our institutional protocol. All
absorbed dose calculations are based on the organ-level S
values (e.g. whole ROB to bone marrow) [11].
Methods
Patient selection, data acquisition, and image
quantification
Patient selection
This study is based on ten patients, with five patients suffer-
ing from somatostatin receptor-positive neuroendocrine
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metastases (P1-P5) and five patients from mCRPC with ex-
pression of PSMA-avid lesions (P6-P10). Details for each
patient are provided in Tables 1 and 2. All patients received
multiple therapy cycles of approximately 3.7 GBq
Lu-177-DKFZ-PSMA-617 (Lu-177-PSMA-617) or 7.4 GBq
Lu-177-[DOTA0,Tyr3]-Octreotate (Lu-177-Octreotate). All
patients except one mCRPC patient showed soft tissue le-
sions on the pre-therapeutic Ga-68-HBED-CC-PSMA or
Ga-68-[DOTA0,Tyr3]-Octreotate PET/CT scans, while all
prostate-specific membrane antigen (PSMA) patients and
two NET patients additionally presented with bone metas-
tases (Tables 1 and 2). The local ethics committee approved
the study protocol and did not desire any written consent
for the study entry. The study is based on retrospective and
anonymised patient data.
Data acquisition
Data for dosimetry were acquired during a routine 4-day
in-patient stay following the radiopharmaceutical injec-
tion, in conjunction with standard clinical examinations.
All patients received a 15-min one-bed abdominal SPECT
scan and a 20-min whole-body planar scintigraphy at 24,
48, and 72 h post-injection (p. i.) on a dual-headed Symbia
T2 SPECT/CT (Siemens Medical Solutions, Erlangen,
Germany). Counts were detected for the photopeak win-
dow of 208 keV (width 15%) by the usage of a
medium-energy low-penetration collimator. Two add-
itional scatter windows were measured at 170 keV (width
15%) and 240 keV (width 10%). A low-dose AC-CT was
acquired at the first image acquisition session for
anatomical correlation and attenuation correction during
quantitative SPECT reconstruction. For the determination
of the absorbed dose to the bone marrow from the activity
circulating in the blood, five venous blood samples were
drawn from the site contralateral to injection at 30 and
80 min p. i. and 24, 48, and 72 h p. i. [9, 20].
SPECT image reconstruction and quantification
Quantitative SPECT images were reconstructed as de-
scribed by Delker et al. [9] via a rotation-based, penalised,
one-step-late ordered subset expectation maximisation al-
gorithm, which included corrections for scatter, attenuation,
and distance-dependent geometrical collimator blur. At-
tenuation correction was performed for each SPECT scan
via the AC-CT, which was acquired along with the SPECT
scan 24 h post-injection. To apply the attenuation correc-
tion, especially to the SPECT scans 48 and 72 h p. i., the
single AC-CT was co-registered onto an initial SPECT re-
construction without attenuation correction by using a rigid
body co-registration algorithm with six degrees of freedom
(PMOD Version 3.609, PMOD Technologies, Zurich,
Switzerland). If only one AC-CT is acquired for sequential
SPECT imaging, special care has to be taken to minimise
misregistration between SPECT images and separately ac-
quired CT scans, as such a misalignment can distort the
proper attenuation correction and, thus, activity quantifica-
tion. This is in principal also true for serial SPECT and CT
imaging, as even within a single image acquisition session
patient movements cannot be entirely avoided. Scatter cor-
rection employed the triple energy window (TEW) method.
Table 1 Characteristics of all NET patients included in this study for Lu-177-Octreotate therapy
Octreotate P1 P2 P3 P4 P5
Sex M M F F F
Age 68 66 61 47 73
Activity investigated cycle
[MBq]
7654 7425 7420 7409 7410
Diagnosis NET small intestine NET NET terminal
ileum
NET pancreas NET stomach
Metastases (PET/CT)
- Extend Medium Medium Medium Medium Medium
- Type (VIS = visceral,
LYM = lymph,
OSS = osseous)
Mainly VIS (liver),
LYM
Mainly LYM, VIS
(liver)
Mainly VIS (liver),
LYM, OSS
Mainly LYM, VIS (liver and other) Mainly VIS (liver),
OSS
Proliferation index Ki67 3–4% Ki67 5–10% Ki67 1% Ki67 10% Ki67 10%
Pre-therapies SSA-analogues Interferon alpha Hemicolectomy,
SSA-analogues,
radioembolization
Chemotherapy (stroptozotocin/5-FU,
dacarbazapin, capecitabin/Te-modal)
SSA-analogues,
bisphosphonate
therapy
Blood pre-therapy
- Leukocytes [G/l] 7.76 10.4 3.79 3.93 10.2
- Erythrocytes [T/l] 4.58 4.50 4.43 3.73 4.42
- Thrombocytes [G/l] 207 294 297 177 303
- Haematocrit 0.421 0.442 0.373 0.341 0.399
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Correction for distance-dependent collimator blur made
use of a Gaussian blur model. Corrections for partial vol-
ume effects and dead time were not applied. For conversion
of the measured counts per second and per voxel to Bec-
querel per millilitre, an appropriate calibration factor was
determined. Therefore, we used a large cylinder of approxi-
mately 20 cm diameter, which was filled with a known ac-
tivity concentration and which has been imaged and
reconstructed via the same protocol [9, 15, 20].
Planar image correction and calibration
For each patient, all acquired whole-body planar images
were corrected for scatter and attenuation on a pixel
basis via a dedicated MATLAB routine (Fig. 1) [16, 20,
21]; for the correction of scatter, the TEW method was
applied, as for the quantitative SPECT images. For the
attenuation correction, a linear projection of μ values
along the ventral axis of the patient was created from
the diagnostic CT image of the pre-therapeutic Ga-68
PET/CT scan, which covered nearly the whole patient
body from the middle of the head to approximately the
knees. Therefore, a conversion between the Hounsfield
units (HUs) in the diagnostic CT and the μ values at
208 keV was established by acquiring a CT scan of a
Gammex tissue phantom (Gammex 467; Gammex, Inc.,
Middleton, WI) with 16 tissue rods of known compos-
ition and thus known attenuation characteristics [22].
The μ values of all rods were plotted against the
measured HUs, and a bilinear fit model (range 1:
HU = (− 688;0); range 2: HU = (0;1127)) was applied to
the whole data set [15, 22]. This calibration curve allows
for the assignment of μ values to a continuous range of
HUs. The lower arms and legs as well as a part of the
head were not included in the PET/CT data, as the arms
are usually positioned above the head during the PET/
CT scan and as the PET/CT scan is usually not acquired
over the entire patient length. By contrast, the arms,
legs, and head are fully included in the whole-body pla-
nar images, and an appropriate μ value has to be defined
for each segment (Fig. 1). Thus, mean μ values derived
from three patients with PET/CT acquisitions of the
head, legs, and arms were assigned to the missing seg-
ments. Therefore, all segments—the part visible on the
PET/CT and the missing parts of the head, arms, and
legs—were delineated on the co-registered whole-body
planar images (delineation and rigid body co-registration
via PMOD Version 3.609). The resulting map of the re-
gions of interest (ROI) was saved, with each ROI seg-
ment being characterised via a defined value. This ROI
map was then loaded by a self-designed MATLAB rou-
tine, which assigned the defined μ value to each segment
according to the ROI number. Afterwards, the resulting
whole-body integral μ-map was blurred via a Gaussian
filter with a width approximating an average resolution
of the gamma camera (geometric resolution of full width
at half maximum of 11 mm at 10 cm). Pixel-wise attenu-
ation correction was finally performed in conjunction
with geometric averaging of both planar views (conju-
gate view method) [21].
Calibration of whole-body planar images was performed
via the corresponding quantitative abdominal SPECT by
using the fact that ideally the total activity ASPECT within
the quantitative SPECT should be correlated to the
number of counts per second (cps) xplanar in the planar ab-
dominal counterpart multiplied by an appropriate calibra-
tion factor:
Fig. 1 Workflow for planar image quantification shown for patient P8. Anterior and posterior views for all three energy windows (24 h p. i.;
photopeak and both scatter windows) and attenuation map based on the projected patient-specific CT from the PET/CT scan
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ASPECT ¼ xplanar∙Cplanar;SPECT: ð1Þ
Cplanar, SPECT denotes the SPECT-based calibration fac-
tor in units of Bq/cps.
Bone marrow dosimetry formalism
To derive total bone marrow absorbed doses (DBM← total),
a sum of the bone marrow self-absorbed dose from the ac-
tivity in the blood (DBM← blood) as well as the bone mar-
row cross-absorbed dose by major organs (DBM← organs),
tumours (DBM← tumours), and the ROB (DBM← ROB) was
considered according to the findings of previous studies
[5, 7–9, 13]. If not indicated otherwise, the general term
bone marrow always refers to the red or active bone mar-
row, i.e. the radiation-sensitive part of the bone marrow
mixture [23]. The dose contribution of each source com-
ponent to the bone marrow was estimated according to
the guidelines of the European Association of Nuclear
Medicine (EANM) [11]. Following the Medical Internal
Radiation Dose (MIRD) formalism underlying the EANM
guidelines, the absorbed dose to the bone marrow origin-
ating from a specified source region (DBM← source) was cal-
culated according to Eq. (2) [24]:
DBM←source ¼ SBM←source∙~Asource
¼ SBM←source∙
Z ∞
0 injectionð Þ
Asource tð Þdt:
ð2Þ
~Asource describes the time-integrated activity per source
region and SBM← source the corresponding S value or
absorbed dose conversion factor. Asource(t) corresponds to
the source-specific time-activity curve (TAC), which is based
on sequential measurements and a subsequent fit to the
source time-activity measurements. For this study, S values
are taken from the public tabulations of Monte Carlo simula-
tion results for the standardised male (Lu-177-PSMA-617
and Lu-177-Octreotate therapy) or female (Lu-177-Octreo-
tate therapy) anthropomorphic phantom as provided,
amongst other phantoms, by RADAR [25]. To adjust these
phantom-based S values to the patient-specific conditions, all
S values were scaled according to a non-linear mass scaling
approach developed by Traino et al. [26].
Absorbed dose from the blood time-integrated activity
In the absence of specific binding to the bone marrow
or blood cells, as indicated for PSMA therapy [27, 28],
the bone marrow self-absorbed dose is solely given by
the activity in the extracellular fluid of the marrow tissue
[11]. The activity in the extracellular fluid of the bone
marrow can be derived from the activity concentration
in the blood plasma (blood method), multiplied with the
red marrow extracellular fluid fraction (RMECFF = 0.19)
of the bone marrow [11, 29, 30]. The activity concentra-
tion in the plasma can in turn be determined from the
activity concentration in the blood ( ½~Ablood ) and the
patient-specific haematocrit (HCT), if there is no specific
binding to the blood cells [11]. This yields to:
DPSMABM←blood ¼ ~Ablood
 
∙RMBLR∙mBM;patient∙SBM←BM;phantom∙
mBM;phantom
mBM;patient
 a
;
ð3:1Þ
RMBLRPSMA ¼ RMECFF
1−HCT
: ð3:2Þ
where RMBLR corresponds to the red-marrow-to-blood
activity concentration ratio [11]. m denotes the bone
marrow (BM) or whole-body (WB) masses (mBM/WB,
phantom/patient) of either the phantom or of the patient
[11, 26].
For Lu-177-Octreotate therapy, it holds that:
DOCTREOBM←blood ¼ ~Ablood
 
∙RMBLR∙mBM;patient∙SBM←BM;phantom∙
mBM;phantom
mBM;patient
 a
:
ð3:3Þ
RMBLROCTREO ¼ 1 ð3:4Þ
[11, 13]. To scale the male and female S values to the
patient anatomy, an exponent of a= 1.001 and a= 0.992 was
proposed for Lu-177-PSMA-617 and Lu-177-Octreotate
therapy, respectively [26]. To derive the patient-specific
blood TAC, 1 ml of blood of each sample was pipet-
ted into a test tube and measured within a Cobra
Gamma Counter (Packard Instrument Company, Inc.,
Meriden, CT), which has been previously calibrated
via five 1-ml test samples of known activity concen-
tration. For the calculation of the time-integrated
blood activity concentration, a bi-exponential model
was fitted to the time-activity data, followed by inte-
gration from zero to infinity according to Eq. (2).
Absorbed dose from the remainder of body and major
organs
Via subtraction of the time-integrated activity in the extracel-
lular fluid and the time-integrated activity of the main
accumulating organs from the whole-body, the respective
ROB time-integrated activity ( ~AROB ) was determined. The
whole-body and organ time-integrated activities, ~AWB and
~Aorgan , were determined from a mono-exponential fit to the
three measurement points at 24, 48, and 72 h post-injection.
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All organ activities were derived from the sequential SPECT
images, while for the determination of the whole-body activ-
ity, the sequential whole-body planar images were used. The
kidneys were considered as main accumulating organs for
both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, ac-
cording to the previous studies assessing dosimetric esti-
mates [5, 7–9]. The patient-specific volumes of interest
(VOIs) for the kidneys were defined based on a percent iso-
contour of the organ maximum and of the quantitative
SPECT at 24 h p. i. (PMOD Version 3.609), since images
taken at early time points offer a high signal-to-background
ratio for organ delineation. We adjusted the isocontour level
for each patient in the best way with the usage of the CT as
guidance. For all patients, an isocontour level of 30–40% was
found to be appropriate. All kidney VOIs were copied to the
following SPECT scans 48 and 72 h p. i., which were
co-registered onto the SPECT scan 24 h p. i. in advance. We
manually re-positioned, i.e. shifted or rotated, the kidney
VOIs in case of imperfect co-registration of the individual
SPECT time points. For Lu-177-Octreotate therapy, the liver
and spleen were additionally included in the bone marrow
absorbed dose from the organs [5]. For the patient-wise de-
lineation of the liver and spleen, a similar approach as for
the kidney definition was chosen using a 10 to 15% isocon-
tour for the liver and a 30 to 40% isocontour for the spleen.
The lower isocontour for liver delineation can be explained
by the fact that NET patients often exhibit liver metastases,
which lead to a heterogeneous activity accumulation with
multiple hot spots.
The bone marrow absorbed dose from the ROB is fi-
nally given by the following formula according to Hin-
dorf et al. with adjusted exponents as proposed by
Traino et al. [11, 26]:
~AROB ¼ ~AWB− ~Ablood
 
∙RMBLR∙mBM;patient−
X
all organs
~Aorgan;
ð4:1Þ
DBM←ROB ¼ ~AROB∙
 
SBM←WB;phantom∙
mWB;phantom
mWB;patient
 b
∙
mBM;phantom
mBM;patient
 c
−SBM←BM;phantom∙
mBM;phantom
mROB;patient
∙
mBM;phantom
mBM;patient
 a
−
X
all organs
SBM←organ;phantom∙
morgan;phantom
mROB;patient
∙
mBM;phantom
mBM;patient
!
:
ð4:2Þ
Eq. (4.2) considered all phantom- and patient-specific
whole-body, ROB, bone marrow, and organ masses
mWB/ROB/BM/organ, phantom/patient for S value scaling. For
male and female patients, b = 0.896 and b = 0.894 as well
as c = 0.963 and c = 0.970 were used, as proposed by
Traino et al. [26]. The bone marrow absorbed dose contri-
bution of each individual organ is given by:
DBM←organ ¼ ~Aorgan∙SBM←organ;phantom∙
morgan;phantom
morgan;patient
∙
mBM;phantom
mBM;patient
:
ð5Þ
Due to the high tumour load, as it is frequently observed
in Lu-177-PSMA-617 therapy and sometimes in Lu-177-
Octreotate therapy, we included all tumour activities in
the ROB activity and the ROB S value was applied. As all
patients investigated for Lu-177-Octreotate therapy suf-
fered from liver metastases, the tumour activities had to
be removed from the healthy liver activity for each time
point. Therefore, tumour VOIs were delineated on the
SPECT 24 h p. i. based on a 40% isocontour and trans-
ferred to the following SPECT scans, as it was the case for
the determination of the organ activities.
Hybrid imaging for determination of the ROB cross-
absorbed dose to the bone marrow
Reference dosimetry protocol
For the reference protocol (RP), the bone marrow
absorbed dose from the ROB is determined from all three
available whole-body planar scans (Fig. 2). For the total
bone marrow absorbed dose, the absorbed dose from the
three constituents, organs, blood, and ROB, was summed.
For each dose constituent, the percentage contribution
(PCconstituent) to the total bone marrow absorbed dose was
calculated:
PCconstituent ¼ DBM←constituentDBM←total ∙100%: ð6Þ
Hybrid dosimetry protocol
The proposed hybrid protocol (HP) uses a single whole-
body image and sequential single-bed quantitative
SPECT acquisitions of the abdomen to determine the
ROB TAC, instead of deriving the ROB TAC from se-
quential whole-body planar imaging.
First, the abdominal effective decay constant λSPECT
was derived via a mono-exponential fit to the total activ-
ity in the SPECT scans 24, 48, and 72 h post-therapy.
Especially, all organs and all tumours were included in
the fitting of the TAC, as it was the case for the deter-
mination of ~AWB from the reference protocol. This ef-
fective decay constant λSPECT serves as a surrogate for
the reference-protocol-based whole-body effective decay
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constant (Fig. 2). The mono-exponential SPECT-based ab-
dominal TAC was then scaled with a chosen base point. This
base point is defined via the whole-body activity AWB(t
∗) of a
single whole-body planar image acquired at an arbitrary time
point t∗∈ 24, 48, or 72 h post-therapy. The resulting pseu-
do-whole-body TAC AWB, pseudo(t) is intended to
serve as an estimate of the reference-protocol-based
whole-body TAC (Eq. (7.1)) and can be further used
to determine a pseudo-whole-body time-integrated
activity ~AWB;pseudo (Eq. (7.2)).
AWB;pseudo tð Þ ¼ AWB;pseudo tð Þ∙ exp −λSPECT∙ t−tð Þð Þ;
ð7:1Þ
~AWB;pseudo ¼
Z ∞
t¼0
AWB;pseudo t
0ð Þdt0
¼ AWB t
ð Þ∙ exp λSPECT∙tð Þ
λSPECT
¼ AWB t
ð Þ∙ exp λSPECT∙tð Þ∙T 1=2;SPECT
ln 2ð Þ :
ð7:2Þ
T1/2, SPECT denotes the SPECT-based effective half-life.
Comparison of reference and hybrid absorbed dose values
Based on the hybrid model given in Eqs. (7.1) and
(7.2), the bone marrow absorbed dose from the ROB
can be estimated by Eqs. (4.1) and (4.2). In this work,
we investigated a combination of the sequential ab-
dominal SPECT with the whole-body planar images at
24, 48, or 72 h p. i., where each whole-body planar
image was individually calibrated via the quantitative
SPECT at the corresponding time point (Fig. 2).
These different hybrid protocols were further denoted
as HP24, HP48, and HP72. The agreement of the
bone marrow absorbed doses from the ROB, as deter-
mined via the HP and the RP, was assessed. There-
fore, the percentage deviation between absorbed dose
estimates (PDdose; Eq. (8)) was calculated, and a stat-
istical test for correlation was performed (MATLAB
Pearson correlation analysis).
PDdose ¼
DHP24=HP48=HP72−DRP
DRP
 
∙100%: ð8Þ
Furthermore, the same analysis was performed re-
garding the total bone marrow absorbed dose esti-
mates composed of all available constituents: the ROB
(including tumours), the explicitly analysed organs,
and the contribution of the blood activity. While the
application of the hybrid protocol affects the bone
marrow absorbed dose from the ROB, all other con-
stituents were not altered.
Fig. 2 Illustration of the reference protocol (RP) and the proposed hybrid protocol (HP); for the hybrid protocol, the sequential whole-body planar
imaging is replaced by a single whole-body planar acquisition at an appropriate time point at 24, 48, or 72 h p. i. (HP24, HP48, HP72); QSPECT
indicates quantitative SPECT
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Comparison of hybrid and reference ROB TAC parameters
For a mono-exponential TAC, the time-integrated activ-
ity is calculated as the product of the effective half-life
T1/2 and the y-axis intercept A0 of the fit function:
~A ¼ A0
ln 2ð Þ ∙T 1=2: ð9Þ
The proposed hybrid protocol assumes that ideally,
the SPECT-based abdominal effective half-life is equal to
the whole-body effective half-life. However, in reality,
differences in both half-lives will lead to deviations in
the area under the whole-body TACs derived from the
reference protocol and hybrid protocol, and thus in the
respective whole-body and ROB time-integrated activ-
ities. Simultaneously, these deviations in the course of
the TACs may affect the y-axis intercepts of the
reference-protocol-based and hybrid-protocol-based
TACs. To address this issue, both fit function parameters, ef-
fective half-life and the y-axis intercept, were compared for
the reference protocol, HP24, HP48, and HP72. For a perfect
agreement between the reference-protocol-based and
hybrid-protocol-based ROB time-integrated activities, ~ARP
and ~AHP, the product of the ratio of reference-to-hybrid ef-
fective half-lives ðT1=2;RPT1=2;HPÞ and the ratio of reference-to-hybrid
y-axis intercepts ðA0;RPA0;HPÞ has to yield 1:
~ARP
~AHP
¼ A0;RP
A0;HP
∙
T1=2;RP
T1=2;HP
¼ 1 ð10Þ
Results
Reference dosimetry protocol
Based on the reference protocol, median total bone marrow
absorbed doses were calculated as 12.1 mGy/GBq (range
9.6–15.6 mGy/GBq) for Lu-177-Octreotate and 10.8 mGy/
GBq (range 6.7–16.8 mGy/GBq) for Lu-177-PSMA-617
therapy (Table 3). The blood absorbed dose contribution was
higher for Lu-177-Octreotate compared with Lu-177-
PSMA-617 therapy, with a larger inter-patient variability for
Lu-177-PSMA-617 therapy. The median values were found
to be 59% (range 50–63%) for Lu-177-Octreotate therapy
and 43% (range 13–63%) for Lu-177-PSMA-617, respectively
(Table 3). The median ROB contribution was 34% (range
29–41%) for Lu-177-Octreotate and 45% (range 34–80%) for
Lu-177-PSMA-617 therapy, again with a higher variance of
the patient-specific percentage contributions for Lu-177-
PSMA-617 therapy (Table 3). For Lu-177-PSMA-617 ther-
apy, the higher percentage ROB contribution to the total
bone marrow absorbed dose is on the one hand driven by
the larger tumour load for the investigated mCRPC patients,
as all tumours were included in the ROB compartment. On
the other hand, the percentage contribution of the bone
marrow absorbed dose from the blood is reduced for
Lu-177-PSMA-617 therapy compared with Lu-177-Octreo-
tate therapy due to the weighting of the blood activity with
the patient haematocrit and the RMECFF, yielding an aver-
age weighting factor of 0.3. Furthermore, for the five mCRPC
patients in this study, a lower median effective half-life for
the slow phase of the bi-exponential fit to the blood
time-activity measurements was observed, compared with
the five NET patients (Lu-177-Octreotate, 25 h;
Lu-177-PSMA-617, 14 h; Fig. 3). The major accumulating
organs contributed at maximum 9% (median: all organs 8%,
kidneys 4%, liver 2%, spleen 1%) for Lu-177-Octreotate ther-
apy and 12% (median kidneys 8%) for Lu-177-PSMA-617
therapy (Table 3).
Hybrid protocol and comparison of reference and hybrid
absorbed dose values
For Lu-177-Octreotate therapy, the median deviations of
the bone marrow absorbed dose from the ROB were
found to be 37% (range 29–42%), 23% (range 11–38%),
and 3% (range 1–13%) for the HP24, HP48, and HP72,
respectively, compared with the results obtained via the
reference protocol (Fig. 4a). A very strong and significant
(p < 0.05) correlation between the reference and hybrid
protocol was confirmed for all base points 24, 48, 72 h
p. i. with Pearson correlation coefficients of 0.98, 0.93,
and 0.98. However, a tendency of overestimation of the
bone marrow absorbed dose from the ROB, especially
for the HP24 and the HP48, is noticed (Fig. 5a–c). The
Table 3 Results from the reference protocol. Total bone
marrow absorbed doses (DBM← total) and the percentage
contribution of ROB, blood, and organs to the total bone
marrow absorbed dose. All percentage contributions were
calculated according to Eq. (6)
Patient DBM← total [mGy/GBq] ROB [%] Blood [%] Organs [%]
Octreotate
P1 12.1 29 63 8
P2 9.6 34 60 6
P3 15.6 34 59 7
P4 11.8 36 59 5
P5 12.7 41 50 9
Median 12.1 34 59 8
PSMA-617
P6 10.2 36 56 8
P7 6.7 45 43 12
P8 16.8 80 13 7
P9 14.2 34 63 3
P10 8.3 60 28 12
Median 10.8 45 43 8
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respective deviations for Lu-177-PSMA-617 were found
to be 29% (range 3–46%), 4% (range 1–17%), and 4%
(range 1–18%) (Fig. 4c) with a very strong Pearson cor-
relation of 0.98, 1.00, and 1.00, respectively (Fig. 5d–f ).
The tendency of overestimation of the bone marrow
absorbed dose from the ROB was also evident for the
HP24, but reduced for the HP48 and HP72 (Fig. 5d–f ).
The deviations between the reference and hybrid
protocol were lower for the total bone marrow absorbed
dose estimates compared with those for the ROB alone
(Fig. 4). For Lu-177-Octreotate therapy, median differ-
ences of the total bone marrow absorbed doses were
13% (range 9–17%), 8% (range 4–15%), and 1% (range
0–5%) using the HP24, HP48, and HP72, respectively,
with a very strong and significant (p < 0.05) Pearson cor-
relation of 0.98, 0.96, and 0.99 (Figs. 4b and 5a–c). As it
was the case for the bone marrow absorbed dose from
the ROB alone, especially the use of an early base point
leads to overestimated absorbed dose values (Table 4
and Fig. 5a–c). For Lu-177-PSMA-617 therapy, the me-
dian deviations were found to be 10% (range 2–20%), 3%
(range 0–6%), and 2% (range 0–6%) with a very strong
correlation of 0.99, 1.00, and 1.00, respectively (Figs. 4d
and 5d–f ). The tendency of overestimated absorbed dose
values was particularly evident for the base point 24 h p.
i. (Table 4 and Fig. 5d–f ).
To summarise, for Lu-177-Octreotate, the best agree-
ment with respect to the reference protocol was ob-
tained with the hybrid protocol based on 72 h p. i. for all
patient cases, while for Lu-177-PSMA-617 therapy for
40% of the patients, the time point of 48 h p. i. and for
40% the acquisition of 72 h p. i. was best suited. For one
mCRPC patient, both base points, 48 and 72 h p. i.,
provided the same absolute deviation from the reference
(Table 4).
Comparison of hybrid and reference TAC parameters
For both Lu-177-Octreotate and Lu-177-PSMA-617
therapy, the whole-body effective half-life was shorter
compared with the washout in the abdominal region, ex-
cept for patient P9, who presented with pronounced and
strongly accumulating bone metastasis in the right hip
(Table 5). Median whole-body and abdominal effective
half-lives were found to be 43 h (range 40–62 h) and
61 h (range 53–87 h) for Lu-177-Octreotate therapy and
31 h (range 22–65 h) and 42 h (range 31–67 h) for
Lu-177-PSMA-617 therapy. Table 5 indicates a tendency to
lower whole-body and abdominal effective half-lives for
Lu-177-PSMA-617 compared with Lu-177-Octreotate ther-
apy, except for patient P8, who showed the highest bone
tumour load with strong and persistent retention of the ra-
diopharmaceutical (Fig. 1). The deviation between the ef-
fective half-lives was similar for both therapies with 40%
(range 30–42%) for Lu-177-Octreotate therapy and 46%
(range 4–64%) for Lu-177-PSMA-617 therapy, however,
with a larger observed variability for Lu-177-PSMA-617
therapy (Table 5).
Figure 6 shows examples of fitted reference-protocol-based
whole-body and hybrid-protocol-based whole-body
TACs for both Lu-177-Octreotate (patient P4) and
Lu-177-PSMA-617 (patient P8) therapy. The use of
the SPECT-based effective half-life for the hybrid
protocol leads to an under- and overestimation of the
reference-protocol-based TAC before and after the se-
lected base point. This under- and overestimation is
varying for the HP24, HP48, and HP72 and also affects
Fig. 3 Time-activity curves (TAC) for the bone marrow self-absorbed dose as determined via the blood method and for both Lu-177-Octreotate
(a) and Lu-177-PSMA-617 therapy (b) (according to Eqs. (3.1) and (3.3)); the patient-specific TACs are shown in black, while the median is
presented in red
Gosewisch et al. EJNMMI Research  (2018) 8:76 Page 10 of 16
the y-axis intercept of the hybrid-protocol-based
TACs in comparison to the reference protocol. Figure 7
summarises the patient-specific ratios of the
reference-to-hybrid effective half-lives in comparison to
the ratio of the corresponding y-axis intercepts. The black
line indicates all combinations of effective half-life and y-axis
intercept ratios, for which the reference-protocol-based and
hybrid-protocol-based time-integrated activities are equal.
For Lu-177-Octreotate therapy, the median ratio of the
reference-to-hybrid effective half-lives was found to
be 0.7 (range 0.7–0.8). Simultaneously, the reference-
to-hybrid y-axis intercept ratios increase for the base
points from 24 to 72 h post-therapy. For the HP72,
the combination of effective half-life and y-axis inter-
cept ratios yields to the closest agreement between
the reference-protocol-based and hybrid-protocol-
based time-integrated activities (Fig. 7a). For Lu-177-
PSMA-617 therapy, the median ratio of the reference-
to-hybrid effective half-lives was calculated as 0.7 (range
0.6–1.3). The larger variability in the reference-to-hybrid
effective half-life ratios is also evident in Fig. 7b. For
Lu-177-PSMA-617 therapy, for the time points 48 and
72 h p. i., combinations of reference-to-hybrid effective
half-life ratios and y-axis intercept ratios were found
which result close to a ratio of 1between the
reference-protocol-based and hybrid-protocol-based ROB
time-integrated activities.
Discussion
Although all bone marrow absorbed dose estimates are
well below the typically applied critical threshold of 2 Gy
[5] and no severe marrow toxicities have been observed
for all investigated patients, bone marrow dosimetry is
still a matter of interest. This is particularly true regard-
ing the maximum absorbed dose that can be applied for
patients with progressive cancer disease, who already
underwent several pre-therapies. The absorbed dose esti-
mates determined in this study are in good agreement
with the findings of previous studies for both therapies
[5, 7, 8, 31].
Fig. 4 Percentage deviation (PD) from the reference protocol for the bone marrow absorbed dose from the ROB and the total bone marrow absorbed
dose depending on the base point used for the hybrid protocol (24, 48, or 72 h p. i.). All percentage deviations were calculated according to Eq. (8)
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Table 4 Comparison of the reference and hybrid protocol for different time points of single whole-body planar image acquisition
(24 h p. i.: HP24; 48 h p. i.: HP48; 72 h p. i.: HP72); all calculated total bone marrow absorbed doses (DBM← total) are provided
Patient DBM← total RP [mGy/GBq] DBM← total HP24 [mGy/GBq] DBM← total HP48 [mGy/GBq] DBM← total HP72 [mGy/GBq]
Octreotate
P1 12.1 13.2 12.6 12.1
P2 9.6 10.8 10.3 9.6
P3 15.6 17.1 16.2 15.7
P4 11.8 13.5 12.8 12.3
P5 12.7 14.9 14.7 13.4
Median 12.1 13.5 12.8 12.3
PSMA-617
P6 10.2 11.3 9.6 10.1
P7 6.7 8.1 6.7 7.0
P8 16.8 17.1 17.1 16.8
P9 14.2 13.5 13.6 15.1
P10 8.3 10.0 8.1 8.5
Median 10.2 11.3 9.6 10.1
Fig. 5 Comparison of bone marrow absorbed doses from the ROB and total bone marrow absorbed doses as calculated via the reference
protocol and the HP24, HP48, and HP72 (24, 48, or 72 h p. i.)
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According to the current clinical standard, an uncer-
tainty of at least 10–20% has to be expected for the de-
rived activity and absorbed dose values in case of
quantitative Lu-177 SPECT imaging, and even greater
values might be expected for planar imaging [15–17, 32,
33]. Thus, the results presented in this study suggest
that the application of a hybrid SPECT planar dosimetry
approach based on late whole-body planar images allows
for bone marrow dosimetry which is sufficiently reliable
and applicable in clinical routine. In the case of
Lu-177-Octreotate therapy of patients bearing NET and
with regard to our institutional measurement protocol,
the best time point for whole-body planar imaging was
found to be approximately at 72 h p. i., with maximum
deviations of the total bone marrow absorbed dose of
5% compared to the reference protocol. In patients with
mCRPC receiving Lu-177-PSMA-617 therapy, the
whole-body planar imaging time points 48 and 72 h p. i.
provided comparable total bone marrow absorbed dose
estimates with similar maximum differences of 6% to the
reference-protocol-based full sequential whole-body pla-
nar approach. If five to ten Lu-177-PSMA-617 or
Lu-177-Octreotate therapies are offered per week, the
reduction of whole-body planar scans from three to one
results in a reduction of examination time of 3.5 to 7 h
per week. Simultaneously, the application of the pro-
posed hybrid imaging protocol does not lead to an in-
creased workload for the absorbed dose calculations.
The magnitude of deviations depends on the differ-
ences in the abdominal and whole-body washout and
the positioning of the base point used for scaling of the
mono-exponential pseudo-whole-body TAC. Analysis of
the patient-specific reference-protocol-based and
hybrid-protocol-based TAC parameters revealed that the
use of a prolonged SPECT-based effective half-life is
compensated by a lower y-axis intercept, if a later base
point is selected. The use of a base point later than 72 h
p. i. still has to be investigated; however, such a time
point was unfortunately not available in our institutional
measurement protocol. As expected, the deviations be-
tween the reference and hybrid protocol were larger for
the bone marrow absorbed dose from the ROB com-
pared with the total bone marrow absorbed dose, as the
median ROB contribution to the total absorbed dose
Fig. 6 Whole-body TACs for (a) patient P4 (Lu-177-Octreotate) and (b) patient P8 (Lu-177-PSMA-617) to visualise the impact of the time point of
whole-body planar image acquisition during hybrid-protocol-based calculation of the bone marrow absorbed dose from the ROB (24, 48, or 72 h
p. i.)
Table 5 Comparison of planar-based whole-body (T1/2, WB) and
SPECT-based abdominal effective half-lives (T1/2, SPECT) for Lu-
177-PSMA-617 and Lu-177-Octreotate therapy
Patient T1/2, WB [h] T1/2, SPECT [h]
Octreotate
P1 40 53
P2 43 61
P3 43 56
P4 52 73
P5 62 87
Median 43 61
PSMA-617
P6 22 33
P7 31 50
P8 65 67
P9 39 31
P10 29 42
Median 31 42
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was found to be only 34% for Lu-177-Octreotate therapy
and 45% for Lu-177-PSMA-617 therapy.
The appropriate whole-body planar imaging time
point may have to be determined separately for each
type of therapy. The degree of the deviations between
abdominal and whole-body effective decay constants is
driven by the disease- or therapy-specific retention in
the organs and tumours and the corresponding typical
tumour distribution. The mCRPC patients included in
this study typically showed a larger tumour load com-
pared with the NET patients, which was additionally
strongly varying over the whole patient body. For most
of the mCRPC patients (except P9) included in this
study, the main metastatatic load was located in the
torso, and consequently, the abdominal effective half-life
was larger compared with the whole-body effective
half-life. By contrast, patient P9 suffered from a strongly
accumulating metastasis in the hip, leading to a com-
paratively larger whole-body effective half-life. The larger
variability in the whole-body tumour distribution for
mCRPC patients causes the observed larger spread in
the differences between abdominal and whole-body ef-
fective half-lives. Consequently, a high tumour load out-
side the SPECT field of view might lead to an increased
uncertainty of the proposed hybrid protocol, and this ef-
fect should be further investigated. As it was the case for
most of the mCRPC patients, the investigated NET cases
mainly presented with metastases in the torso, which lead
to an increased retention of the radiopharmaceutical in
the abdomen. However, due to the lower tumour load, the
inter-patient variability in the abdominal and whole-body
effective half-lives was reduced for the NET patients
under study.
The change from one-bed abdominal SPECT imaging
to the imaging of two or more beds could principally im-
prove the proposed hybrid protocol for bone marrow
dosimetry, as an enlarged acquisition area will lead to a
more realistic estimate of the whole-body effective
half-life. Furthermore, the introduction of fast multi-bed
SPECT imaging in the clinical routine would be benefi-
cial for a robust tumour and organ dosimetry over a lar-
ger part of the patient body [15–18]. Attempts to
introduce fast whole-body SPECT imaging into the
clinic already exist [34]. However, the effect of a reduc-
tion of scan time on absorbed dose estimates for Lu-177
therapy still has to be evaluated.
The accuracy of dosimetry based on standardised
organ-level S values is limited, as such S values are in-
herently not capable to fully consider the patient-specific
full 3D functional and anatomical characteristics. The
latter fact remains true, even if a scaling of the S values
to the specific anatomical conditions is applied [6, 14,
35–37]. For Lu-177, the ROB cross-absorbed dose of the
bone marrow is mainly driven by the long-range photon
component, which is more sensitive to the anatomy than
the locally deposited beta absorbed dose. In a previous
study based on Monte Carlo simulations, deviations of
the order of up to 100% were observed, if photon
Fig. 7 Evaluation of hybrid-protocol-based TAC parameters in comparison to the reference protocol for both therapies; the ratio of the reference-
protocol-based and SPECT-based effective half-lives (T1/2,RP/T1/2,HP) and the ratio of the y-axis intercepts for the reference-protocol-based and the
hybrid-protocol-based TACs (A0,RP/A0,HP) are provided; the black curve indicates the optimal case, for which the area under both TACs (AUC)
is equal
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cross-absorbed doses were calculated based on standar-
dised S values [38]. Furthermore, S values are deter-
mined based on the assumption of homogeneous
activity accumulation. However, the activity accumula-
tion in the ROB with the inclusion of tumours is highly
heterogeneous with the degree of heterogeneity being
caused by both tumour load and distribution. With re-
gard to both aspects the limited consideration of the
patient-specific functional and anatomical characteris-
tics, the reliablity of the proposed hybrid protocol can
be well accepted in the framework of organ-level S
values. Moreover, it should also be noted that the exact
bone marrow distribution of each patient is a priori un-
known due to the heterogeneous micro-structure of the
bone marrow and its pathologically highly variable dis-
tribution, which both lead to a highly unspecified target
for bone marrow dosimetry [23]. Particularly, for
mCRPC patients with a high bone tumour load, a dis-
placement of active bone marrow from highly metasta-
sised to tumour-free skeletal sites is possible [39].
Our decision to include all tumours in the ROB repre-
sents a simplified approach for clinical routine bone mar-
row dosimetry. On the one hand, this approach is more
practical, as in case of a high bone tumour load, a manual
determination of the time-integrated activity is not feasible
for each tumour lesion in an acceptable time. On the other
hand, even if a semi-automatic or automatic tumour seg-
mentation is available, tumour-to-bone marrow S values for
both individual tumours and the total tumour distribution
are not available, as tumours are quite variable in shape,
size, and position, and the pre-calculation of all possible S
values is not possible. Thus, at this point, a more simplified
approach was chosen, which considered all tumours at
once within the ROB compartment. The approximation to
use the S value of the compartment in which the tumours
are located to estimate the bone marrow absorbed dose
from lesions has also been applied in previous studies [5].
An alternative way, proposed by Svensson et al. for bone
marrow dosimetry for Lu-177-Octreotate therapy, differen-
tiates the activity distribution in the patient body in low-
and high-activity regions (background vs. main accumulat-
ing organs and tumours) with separate S values applied to
each of both compartments [31]. The resulting bone mar-
row absorbed doses correlated with the change of blood pa-
rameters and were found to be in a similar range compared
to previously published results. Monte Carlo studies may
help in further understanding the effect of such simplifying
assumptions for bone marrow dosimetry.
Conclusions
For both Lu-177-PSMA-617 and Lu-177-Octreotate
therapy, bone marrow dosimetry can be performed via a
single whole-body planar image and a sequential SPECT
(hybrid protocol), provided that this planar image is
acquired at a later time point. Regarding the three im-
aging time points 24, 48, and 72 h, which were available
for this study, the time points of 48 or 72 h p. i. were
found to be suitable for Lu-177-PSMA-617 therapy. For
Lu-177-Octreotate therapy, a time point of 72 h p. i. was
identified as appropriate. This hybrid protocol enables
total bone marrow absorbed dose estimates with a max-
imum deviation of 5–6% compared to a dosimetry
protocol using both sequential planar and SPECT im-
aging. These deviations can be considered acceptable
with regard to the uncertainties which currently have to
be expected for Lu-177 quantitative imaging and bone
marrow dosimetry based on organ-level S values. How-
ever, the proposed hybrid protocol allows for a more
patient-friendly and time-efficient bone marrow dosim-
etry in clinical routine due to the decreased examination
times.
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